Cell therapy trials for lung diseases: progress and cautions.
作者信息
Weiss Daniel J, Ortiz Luis A
出版信息
Am J Respir Crit Care Med. 2013 Jul 15;188(2):123-5. doi: 10.1164/rccm.201302-0351ED.
Abstract
摘要
相似文献
1
Cell therapy trials for lung diseases: progress and cautions.肺部疾病的细胞治疗试验：进展与注意事项
Am J Respir Crit Care Med. 2013 Jul 15;188(2):123-5. doi: 10.1164/rccm.201302-0351ED.
2
[Research and Application of Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis: A Review].[基于干细胞的疗法在特发性肺纤维化中的研究与应用：综述]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2021 May;52(3):373-379. doi: 10.12182/20210560304.
3
Moving stem cell therapy to patients with idiopathic pulmonary fibrosis.将干细胞疗法应用于特发性肺纤维化患者。
Respirology. 2014 Oct;19(7):950-1. doi: 10.1111/resp.12364. Epub 2014 Aug 14.
4
Mesenchymal stem cell treatment for IPF-time for phase 2 trials?间充质干细胞治疗特发性肺纤维化——进入2期试验的时候了？
Lancet Respir Med. 2017 Jun;5(6):472-473. doi: 10.1016/S2213-2600(17)30180-7. Epub 2017 May 26.
5
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.静脉输注异体人骨髓间充质干细胞治疗特发性肺纤维化（AETHER）：一项I期安全性临床试验
Chest. 2017 May;151(5):971-981. doi: 10.1016/j.chest.2016.10.061. Epub 2016 Nov 24.
6
Multipotent Mesenchymal Stromal Cells for Pulmonary Fibrosis?多能间充质基质细胞治疗肺纤维化？
Am J Med Sci. 2019 May;357(5):390-393. doi: 10.1016/j.amjms.2019.02.007. Epub 2019 Feb 13.
7
Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment.干细胞与特发性肺纤维化：机制与治疗
Curr Stem Cell Res Ther. 2015;10(6):466-76. doi: 10.2174/1574888x10666150519092639.
8
[Application of mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis].间充质干细胞在特发性肺纤维化治疗中的应用
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):595-598. doi: 10.3760/cma.j.cn112147-20191017-00698.
9
Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease.用于治疗特发性肺纤维化（IPF）疾病的细胞疗法。
Expert Opin Biol Ther. 2016;16(3):375-87. doi: 10.1517/14712598.2016.1124085. Epub 2015 Dec 15.
10
Idiopathic pulmonary fibrosis: present understanding and future options.特发性肺纤维化：当前认识与未来选择
Eur Respir Rev. 2011 Sep 1;20(121):132-3. doi: 10.1183/09059180.00001511.
引用本文的文献
1
Optimized administration of human embryonic stem cell-derived immunity-and-matrix regulatory cells for mouse lung injury and fibrosis.优化人胚胎干细胞来源的免疫和基质调节细胞在小鼠肺损伤和纤维化中的应用。
Stem Cell Res Ther. 2024 Oct 8;15(1):344. doi: 10.1186/s13287-024-03945-4.
2
The Restoring Effect of Human Umbilical Cord-Derived Mesenchymal Cell-Conditioned Medium (hMSC-CM) against Carbon Tetrachloride-Induced Pulmonary Fibrosis in Male Wistar Rats.人脐带间充质细胞条件培养基（hMSC-CM）对四氯化碳诱导的雄性Wistar大鼠肺纤维化的修复作用
Int J Inflam. 2022 Dec 22;2022:7179766. doi: 10.1155/2022/7179766. eCollection 2022.
3
Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players.特发性肺纤维化：分子和细胞关键因素。
Int J Mol Sci. 2021 Aug 19;22(16):8952. doi: 10.3390/ijms22168952.
4
Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution.剖析间充质干细胞在特发性肺纤维化中的作用：病因还是解决方案。
Front Pharmacol. 2021 Jul 5;12:692551. doi: 10.3389/fphar.2021.692551. eCollection 2021.
5
Examining the Characteristics and Applications of Mesenchymal, Induced Pluripotent, and Embryonic Stem Cells for Tissue Engineering Approaches across the Germ Layers.研究间充质干细胞、诱导多能干细胞和胚胎干细胞在跨胚层组织工程方法中的特性及应用。
Pharmaceuticals (Basel). 2020 Oct 26;13(11):344. doi: 10.3390/ph13110344.
6
Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.源自人类胚胎干细胞的免疫和基质调节细胞可安全有效地治疗小鼠肺损伤和肺纤维化。
Cell Res. 2020 Sep;30(9):794-809. doi: 10.1038/s41422-020-0354-1. Epub 2020 Jun 16.
7
Endothelial Colony-Forming Cells Do Not Participate to Fibrogenesis in a Bleomycin-Induced Pulmonary Fibrosis Model in Nude Mice.内皮祖细胞在裸鼠博来霉素诱导的肺纤维化模型中不参与纤维化形成。
Stem Cell Rev Rep. 2018 Dec;14(6):812-822. doi: 10.1007/s12015-018-9846-5.
8
Interrupted reprogramming of alveolar type II cells induces progenitor-like cells that ameliorate pulmonary fibrosis.肺泡II型细胞重编程中断诱导祖细胞样细胞，改善肺纤维化。
NPJ Regen Med. 2018 Sep 4;3:14. doi: 10.1038/s41536-018-0052-5. eCollection 2018.
9
The Management of Patients With Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者的管理
Front Med (Lausanne). 2018 Jul 2;5:148. doi: 10.3389/fmed.2018.00148. eCollection 2018.
10
Best of Milan 2017-repair of the emphysematous lung: mesenchymal stromal cell and matrix.2017年米兰最佳成果——肺气肿肺的修复：间充质基质细胞与基质
J Thorac Dis. 2017 Nov;9(Suppl 16):S1544-S1547. doi: 10.21037/jtd.2017.11.41.
本文引用的文献
1
Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing.间质干细胞与特发性肺纤维化。临床检测的潜力。
Am J Respir Crit Care Med. 2013 Jul 15;188(2):133-40. doi: 10.1164/rccm.201207-1204PP.
2
A placebo-controlled, randomized trial of mesenchymal stem cells in COPD.骨髓间充质干细胞治疗 COPD 的安慰剂对照、随机临床试验。
Chest. 2013 Jun;143(6):1590-1598. doi: 10.1378/chest.12-2094.
3
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.间充质基质细胞（SafeCell）细胞疗法的安全性：临床试验的系统评价和荟萃分析。
PLoS One. 2012;7(10):e47559. doi: 10.1371/journal.pone.0047559. Epub 2012 Oct 25.
4
Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.经心内膜注射异体与自体骨髓间充质干细胞治疗缺血性心肌病的比较：POSEIDON 随机试验。
JAMA. 2012 Dec 12;308(22):2369-79. doi: 10.1001/jama.2012.25321.
5
Stem cells and pulmonary fibrosis: cause or cure?干细胞与肺纤维化：病因还是治疗方法？
Proc Am Thorac Soc. 2012 Jul;9(3):164-71. doi: 10.1513/pats.201201-010AW.
6
Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP.探讨特发性肺纤维化和类风湿关节炎-寻常型间质性肺炎患者骨髓间充质干细胞中端粒酶/端粒系统。
J Inflamm (Lond). 2012 Jul 2;9(1):27. doi: 10.1186/1476-9255-9-27.
7
Mesenchymal stromal cells: new directions.间质基质细胞：新方向。
Cell Stem Cell. 2012 Jun 14;10(6):709-716. doi: 10.1016/j.stem.2012.05.015.
8
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.泼尼松、硫唑嘌呤和 N-乙酰半胱氨酸治疗肺纤维化。
N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20.
9
Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation.对接受间充质基质细胞治疗的人类组织进行分析表明，其长期植入有限，不存在异位组织形成。
Stem Cells. 2012 Jul;30(7):1575-8. doi: 10.1002/stem.1118.
10
Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.特发性肺纤维化的干细胞治疗：方案建议。
J Transl Med. 2011 Oct 21;9:182. doi: 10.1186/1479-5876-9-182.
Zotero 插件